At the news
? BEARISHIMPACT 6/10 6-K filed Aug 4, 2026 at 06:02 ET
Smith & Nephew reported H1 2026 revenue of $3,097M (+2.3% underlying, +4.6% reported) and Q2 revenue of $1,597M (+1.6% underlying). While trading profit grew 8.1% to $566M and EPSA rose 11.0% to 47.7 cents, the company cut full-year revenue guidance from ~6% to ~4% due to weakness in US Orthopaedics and Advanced Wound Bioactives. The miss on top-line guidance and ongoing structural headwinds in Knee Implants and skin substitutes outweigh the profit beat and $500M buyback, making this a bearish read-through for the stock.
- Q2 underlying revenue growth of 1.6% missed expectations; full-year revenue guidance cut from ~6% to ~4%
- H1 trading profit up 8.1% to $566M, driven by $130M in efficiency savings and tariff refunds
- US Knee Implants declined -7.2% in Q2; US Hip Implants declined -1.5% after four quarters of above-market growth
- Advanced Wound Bioactives revenue fell -12.7% underlying in Q2 due to skin substitute reimbursement changes
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access